US EditionDrugmaker Sinergium to share bird flu vaccine data globally, says WHO
- The World Health Organization announced a project to develop bird flu vaccines in poorer countries using messenger RNA technology on July 29.
- Sinergium plans to establish proof-of-concept for its candidate vaccines, sharing resources with manufacturers in poorer countries.
- The WHO maintains that while the risk to the public from avian influenza is low, it could lead to a future pandemic due to its animal circulation.
20 Articles
20 Articles
La Organización Mundial de la Salud (OMS) anunció este lunes una iniciativa para desarrollar vacunas contra la gripe aviar en los países más pobres o en vías de desarrollo con la tecnología del ARN mensajero, un proyecto liderado por una farmacéutica argentina. La empresa biofarmacéutica Sinergium Biotech, en Argentina, encabeza el proyecto y comenzó a desarrollar vacunas candidatas contra el virus de la gripe aviar H5N1, indicó la OMS en un com…
Drugmaker Sinergium to share bird flu vaccine data globally, says WHO
Bird flu vaccine developer Sinergium Biotech will share its data with manufacturers in low and middle-income countries to help to accelerate a fair rollout if a pandemic occurs, the World Health Organization said on Monday.
The Sinergium Biotech must first, in the pre-clinical phase, establish proof that the concept of candidate vaccines can work. The World Health Organization (WHO) announced, on Monday (29), an initiative to develop vaccines against avian flu in the poorest or developing countries with mRNA technology, led by an Argentine pharmaceutical company.
WHO spearheads new initiative for mRNA bird flu vaccine advancement
The World Health Organization announced Monday a new project to accelerate the development in poorer countries of vaccines for human bird flu infections using cutting-edge messenger RNA technology. The WHO said Argentinian manufacturer Sinergium Biotech would lead the effort and had already begun developing candidate H5N1 vaccines. The bird flu H5N1 first emerged in 1996, but since 2020 an exponential growth in outbreaks in birds has occurred in…
In response to the emergence of a new H5N1 avian flu variant and an increase in cases among humans in the Asia-Pacific region, WHO is promoting the development of an ARN messenger-based vaccine. The WHO announced a new initiative on Monday to develop ARN messenger-based vaccines against avian flu in low and middle-income countries, which was decisive against Covid-19. The project is headed by the Argentine biopharmaceutical company Sinergium Bio…
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
